# A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung

> **NCT05470595** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Technische Universität Dresden** · enrollment: 67 (estimated)

## Conditions studied

- Large Cell Neuroendocrine Carcinoma of the Lung

## Interventions

- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT05470595
- **Lead sponsor:** Technische Universität Dresden
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-18
- **Primary completion:** 2028-01-31
- **Final completion:** 2029-01-31
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05470595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05470595, "A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05470595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*